Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) was the target of a significant growth in short interest in January. As of January 30th, there was short interest totaling 757,655 shares, a growth of 458.7% from the January 15th total of 135,611 shares. Based on an average daily trading volume, of 1,844,236 shares, the days-to-cover ratio is presently 0.4 days. Currently, 2.1% of the company’s stock are sold short. Currently, 2.1% of the company’s stock are sold short. Based on an average daily trading volume, of 1,844,236 shares, the days-to-cover ratio is presently 0.4 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Adlai Nortye in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Adlai Nortye has an average rating of “Reduce”.
View Our Latest Stock Report on ANL
Adlai Nortye Stock Down 4.6%
Adlai Nortye Company Profile
Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.
Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.
The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.
Read More
- Five stocks we like better than Adlai Nortye
- They just tried to kill gold
- Is THIS the Next Big Money Rush?
- Wall Street Legend Names #1 Stock of 2026 Live On-Camera
- ISPC: From Small Cap to Life Sciences Market Disruptor!
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
